Home > Insider Trading > Filing (0001209191-24-001957)

Filing Details

Accession Number:: 0001209191-24-001957
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-19 18:02:25
Reporting Period:: 2024-01-17

Accepted Time:: 2024-01-19 18:02:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Kalvista Pharmaceuticals Inc.	KALV	Pharmaceutical Preparations (2834)	200915291

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1615979	Y Bong Koh	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1698082	P Nimish Shah	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1738048	Venrock Healthcare Capital Partners Iii, L.p.	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1738053	Vhcp Management Iii, Llc	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1750761	Vhcp Co-Investment Holdings Iii, Llc	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1808512	Venrock Healthcare Capital Partners Eg, L.p.	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1808518	Vhcp Management Eg, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-17	78,925	$12.60	4,394,971	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2024-01-18	39,680	$12.51	4,434,651	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2024-01-19	25,000	$12.43	4,459,651	No	4	P	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Funds
No	4	P	Indirect	By Funds
No	4	P	Indirect	By Funds

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.53 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Consists of (i) 970,401 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 97,074 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,327,496 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.40 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Consists of (i) 980,833 shares held by VHCP3; (ii) 98,117 shares held by VHCP Co-3; and (iii) 3,355,701 shares held by VHCP EG.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.21 to $12.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Consists of (i) 980,833 shares held by VHCP3; (ii) 98,117 shares held by VHCP Co-3; and (iii) 3,380,701 shares held by VHCP EG.